Radiochemistry and In Vivo Imaging of [ 45 Ti]Ti-THP-PSMA
Molecular Pharmaceutics · 2024
DOI: 10.1021/acs.molpharmaceut.3c00917 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Shefali Saini und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben. Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Titanium-45 (45Ti) is a radionuclide with excellent physical characteristics for use in positron emission tomography (PET) imaging, including a moderate half-life (3.08 h), decay by positron emission (85%), and a low mean positron energy of 0.439 MeV. However, challenges associated with titanium chemistry have led to the underdevelopment of this radionuclide for incorporation into radiopharmaceuticals. Expanding on our recent studies, which showed promising results for the complexation of 45Ti with the tris hydroxypyridinone (THPMe) chelator, the current work aimed to optimize the chemistry and imaging attributes of [45Ti]Ti-THP-PSMA as a new PET radiopharmaceutical.
Methods
Radiolabeling of THP-PSMA was optimized with [45Ti]Ti-citrate at varying pHs and masses of the precursor. The stability of the radiolabeled complex was assessed in mouse serum for up to 6 h. The affinity of [45Ti]Ti-THP-PSMA for prostate-specific membrane antigen (PSMA) was assessed using LNCaP (PSMA +) and PC3 (PSMA -) cell lines. In vivo imaging and biodistribution analysis were performed in tumor-bearing xenograft mouse models to confirm the specificity of the tumor uptake. Results. > 95% of radiolabeling was achieved with a high specific activity of 5.6 MBq/nmol under mild conditions. In vitro cell binding studies showed significant binding of the radiolabeled complex with the PSMA-expressing LNCaP cell line (11.9 ± 1.5%/mg protein-bound activity) compared to that with the nonexpressing PC3 cells (1.9 ± 0.4%/mg protein-bound activity). In vivo imaging and biodistribution studies confirmed specific uptake in LNCaP tumors (1.6 ± 0.27% ID/g) compared to that in PC3 tumors (0.39 ± 0.2% ID/g).
Conclusion
This study showed a simple one-step radiolabeling method for 45Ti with THP-PSMA under mild conditions (pH 8 and 37 °C). In vitro cell studies showed promise, but in vivo tumor xenograft studies indicated low tumor uptake. Overall, this study shows the need for more chelators for 45Ti for the development of a PET radiopharmaceutical for cancer imaging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States.
- Department of Chemistry, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States.
- School of Biomedical Engineering and Imaging Sciences, King's College London, London SE1 7EH, U.K.
ORCID-Profile: Shefali Saini, Philip J Blower
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Saini, S., Mullen, G. E. D., Blower, P. J., & Lapi, S. E. (2024). Radiochemistry and In Vivo Imaging of [ 45 Ti]Ti-THP-PSMA. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00917
Vancouver
Saini S, Mullen GED, Blower PJ, Lapi SE. Radiochemistry and In Vivo Imaging of [ 45 Ti]Ti-THP-PSMA. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.3c00917
BibTeX
@article{Saini2024,
author = {Saini, Shefali and Mullen, Gregory E D and Blower, Philip J and Lapi, Suzanne E},
title = {Radiochemistry and In Vivo Imaging of [ 45 Ti]Ti-THP-PSMA},
journal = {Molecular Pharmaceutics},
year = {2024},
doi = {10.1021/acs.molpharmaceut.3c00917}
}
EUVIMED